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Connective tissue growth factor: Potential role in glomerulo- tion, and their relative contribution to the ultimate clini-
sclerosis and tubulointerstitial fibrosis. Transforming growth cal outcome of end-stage renal disease.
factor beta (TGF-b) is a pivotal driver of glomerulosclerosis A key cytokine, intimately involved in the pathogene-
and tubulointerstitial fibrosis in renal diseases. Because TGF-b
sis of glomerulosclerosis and tubulointerstitial fibrosis,also plays important anti-inflammatory and antiproliferative
is transforming growth factor-b (TGF-b) [1–4]. TGF-broles in mammalian systems, there has been a recent drive to
elucidate downstream mediators of TGF-b’s pro-fibrotic effects augments matrix protein production while simultaneously
with the ultimate goal of developing new anti-fibrotic strategies abrogating matrix degradation [2]. Sustained activation
for treatment of chronic diseases. Connective tissue growth of TGF-b, as occurs in renal scarring, results in a self-
factor (CTGF) belongs to the CCN family of immediate early
perpetuating cycle of matrix deposition and relentlessresponse genes. Several lines of evidence suggest that CTGF
tissue injury. Inhibition of TGF-b bioactivity attenuatesis an important pro-fibrotic molecule in renal disease and that
CTGF contributes to TGF-b bioactivity in this setting. CTGF extracellular matrix (ECM) deposition and progression
expression is increased in the glomeruli and tubulointerstium of fibrosis in experimental renal injury [2, 5, 6]. Long-
in a variety of renal disease in association with scarring and term direct inhibition of TGF-b in the clinical setting,
sclerosis of renal parenchyma. In model systems in vitro, mes-
however, presents several theoretical problems. In addi-angial cell CTGF expression is induced by high extracellular
tion to its profibrotic activity, TGF-b has also antiprolif-glucose, cyclic mechanical strain and TGF-b. Recombinant
erative and anti-inflammatory effects [6, 7]. These con-human CTGF augments the production of fibronectin and type
IV collagen by mesangial cells and the effects of high glucose siderations have focused investigators on downstream
on mesangial cell CTGF expression and matrix production are or parallel mediators of tissue fibrosis that may yield to
attenuated, in part, by anti-TGF-b antibody. In aggregate, these
pharmacological intervention without adverse effects onobservations identify CTGF as an attractive therapeutic target
cell cycle control [6].in fibrotic renal diseases.
Connective tissue growth factor (CTGF) is one such
mediator that is induced by TGF-b, among other stimuli,
and modulates fibroblast cell growth and fibroblast andRegardless of the initiating insult, progression to end-
mesangial cell ECM secretion. CTGF was initially re-stage renal failure in proteinuric kidney disease appears
ported in renal cells in vitro (originally reported in ab-to involve a final common pathway culminating in glo-
stract; Mason et al, J Am Soc Nephrol 8:642A, 1997)merulosclerosis and tubulointerstitial fibrosis. Unfortu-
and has recently been demonstrated in experimental andnately, this relentless loss of residual renal function pro-
human renal fibrosis, in which its expression appears toceeds, albeit at a slower rate, despite blockade of the
correlate with the degree of tubulointerstitial fibrosis.renin-angiotensin system and control of systemic hyper-
CTGF may mediate many of the profibrotic actions oftension. The development of novel therapeutic agents
TGF-b. This review discusses the structure and functionthat interrupt maladaptive fibrotic responses to renal
of CTGF, its relationship to TGF-b, its expression ininjury requires, at first, the comprehensive elucidation
disease, and the potential for pharmacological interven-of the molecular drivers of tissue fibrosis, their interrela-
tion.
Key words: transforming growth factor-b, hyperglycemia, cyclic me-
CTGF: STRUCTURE AND FAMILY MEMBERSchanical strain, diabetic nephropathy, mesangial cells, extracellular
matrix. Connective tissue growth factor is a 36 (nonreduced)
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Fig. 1. Structure of the human connective tissue growth factor (CTGF) gene (modified from Grotendorst [22], Kubota [49], Oemar [89], and
Brigstock [68]).
conserved multimodular structure but exhibit distinctive axis pattern formation, that is, the development of dorsal
structures during embryogenesis (Table 1) [18, 19].functional features. The gene for human CTGF that re-
sides on chromosome 6q23.1, proximal to c-myb, com- CCN family members are cysteine-rich and possess a
secretory signal peptide at the N terminus. All familyprises five exons and four introns (Fig. 1) and was origi-
nally cloned from a human umbilical vein endothelial cell members have four domains: an insulin-like growth factor
(IGF)-binding domain, a von Willebrand factor (VWF)(HUVEC) cDNA library [8]. CTGF is also termed fisp-12
(murine CTGF/mCTGF [9] or bIG-M2 [10]). Other type C repeat domain (wisp-3 has 6 instead of 10 cysteine
residues in this domain), a thrombospondin (TSP) type 1CCN family members include cysteine-rich 61 (cyr 61;
also termed bIG-M1 [10, 11] or cef 10 [12]), nov (nephro- repeat domain, and the C-terminal (CT) domain. An ex-
ception is CTGF-L/rcop-1/wisp-2, which lacks the CT do-blastoma overexpressed gene) [13], wisp-1 [14] (also
termed elm1 [15]), CTGF-L [16] (also termed rCop-1 main. Connecting the VWF type C repeat domain to the
TSP type 1 repeat domain is a region that is highly charged,[17] or wisp-2 [14]), and wisp-3 [14]. Cyr 61/cef 10 and
CTGF/fisp-12 stimulate chemotaxis, adhesion, prolifera- variable, and devoid of cysteines, and it acts as a hinge
connecting the N- and C-terminal halves of the proteinstion, and ECM formation by some cells, whereas nov,
CTGF-L (wisp-2/rCop-1), wisp-3, and wisp-1 (elm1) ex- (Fig. 2). Tsg and sog only contain sequences that resem-
ble domains 1 and 2, respectively. Within family members,hibit features of negative regulators of growth. The Dro-
sophila genes, twisted gastrulation (tsg), and short gas- hCTGF has a 60% homology to CTGF-L [16], a 53%
homology to human nov (novH) [20], a 43% homologytrulation (sog) display weak homology to the CCN family
(approximately 19%) and are involved in dorsal-ventral to human cyr 61 (hcyr 61) [21], and a 36 to 44% homology
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to wisp-2/rCop-1, wisp-1/elm1, and wisp-3. With regard
to differences between species, human CTGF displays
94% homology [22] to murine CTGF (mCTGF)/fisp-12/
bIG-M2 (gene for mCTGF resides in chromosome 10), a
96% homology [23] to rat CTGF (rCTGF), and a 92%
homology [24] to pig CTGF (pCTGF).
Connective tissue growth factor is also a member of
the IGF binding protein (IGFBP) superfamily and was
initially classified as IGFBP-8 [25] on the basis that it is
30 to 38% homologous to IGFBPs 1 to 6 and specifically
binds to IGF. However, this nomenclature was subse-
quently revised at the Fourth International Symposium
on IGFs because of its relatively low affinity binding for
IGFs. CTGF is now termed IGFBP-related protein 2
(IGFBP-RP2) [26–28].
Recently, 10, 12, 16, 18, 19, 20 and 24 kD forms of
CTGF have been demonstrated in different cell types,
tissues, and body fluids [24, 27, 29–34]. The possible
significance of these smaller forms is discussed later in
this article.
CELL SOURCES AND REGULATION OF
EXPRESSION OF CTGF
Connective tissue growth factor was first isolated in
media conditioned with HUVECs [8]. Subsequently, it
has been detected in various fibroblasts [23, 29, 33, 35–40],
endothelial cells [30, 39, 41], cartilagenous cells and chon-
drocytes [32, 42–44], cancer cell lines [27, 45, 46] and
smooth muscle cells (Table 2) [39].
Early studies revealed that TGF-b1 increases CTGF
mRNA levels markedly in human foreskin fibroblasts
(hFFs) [35]. This effect of TGF-b1 with hFFs was seen
within 30 minutes, and CTGF mRNA levels remained
elevated after 24 hours [35]. In contrast, platelet-derived
growth factor (PDGF), epithelial growth factor (EGF),
and fibroblast growth factor (FGF) provoked only a tran-
sient and weak response [35]. CTGF mRNA expression
in response to TGF-b1 was enhanced in the presence of
cycloheximide, indicating that the induction process did
not require de novo protein synthesis [35]. These data
suggest that TGF-b1 is a direct stimulus for CTGF gene
transcription [35]. Subsequent analysis of the CTGF pro-
moter revealed a TGF-b response element (TbRE) [47]
(Fig. 1). This element is distinct from other reported
TGF-b–responsive elements and is not present in other
genes regulated by TGF-b [47]. Moreover, this element
is preserved in fisp-12 and is not found in other CCN
family members [47].
In other in vitro studies, TGF-b increased expression
of CTGF in bovine microvessel endothelial cells [30], in
HCS (a human chrondrosarcoma-derived chondrocytic
cell line) cells [42], and in pancreatic cell lines (Panc-1
and HPAF, human pancreatic adenocarcinoma cell lines
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of ductal organ) [45]; TGF-b1 induced CTGF message
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Fig. 2. Modular structure of connective tissue growth factor.
in human and mouse lung fibroblasts [23], in human secreted peptide present in media conditioned with
HUVECs [8] and serum-stimulated NIH 3T3 cells [50]breast cancer cell line MCF-7, and in cultures of fibro-
blasts from patients with scleroderma [40], and TGF-b2 and undergoes microsomal processing [9]. In hFFs and
mouse fibroblasts, the 38 kD CTGF is reportedly theup-regulated CTGF expression in Hs578T breast cancer
cells [27]. Surprisingly, Boes et al reported that TGF-b1 cell-associated, long-lived, and insoluble form of CTGF,
which is secreted inefficiently [29], whereas the 10 kDor TGF-b2 did not stimulate CTGF mRNA or protein
levels in bovine large vessel endothelial cells [30]. In- CTGF described by Steffen is soluble and biologically
active with these fibroblasts [29]. mCTGF (fisp-12), ondeed, TGF-b1 stimulated CTGF breakdown in bovine
microvessel endothelial cells [30]. In addition to TGF-b, the other hand, is secreted efficiently by NIH 3T3 fibro-
blasts [9, 37] and is present in the cellular fraction, ECM,BMP 2 [42], TGF-a and EGF [45], conditioned monocyte
medium (an atherogenic stimulus) [48] and dexametha- and media of these fibroblasts [37]. The presence of
mCTGF in the culture medium of these cells and itssone (a potent anti-inflammatory agent) [38] have each
been detected to induce CTGF expression in HCS cells, weak association with the ECM implies that mCTGF
may be able to act at areas distant from its site of synthe-pancreatic cell lines, human endothelial cells, and fibro-
blasts, respectively. The inducing effect of dexametha- sis and secretion [37].
The signal transduction events that regulate CTGFsone on CTGF overexpression in fibroblasts was not
mediated by TGF-b1, and this effect was attenuated by synthesis and secretion in response to TGF-b and other
mediators are still being appreciated. As mentioned pre-TNF-a [38]. TNF-a has also been shown to down-regu-
late CTGF expression in bovine endothelial cells, fibro- viously in this article, the CTGF promoter contains a
TbRE. Initial studies indicate that inhibitors of proteinblasts, and smooth muscle cells [39].
Recently, analysis of the 39-untranslated region of the kinase A, but not of tyrosine kinase or protein kinase
C, block TGF-b–stimulated CTGF transcription and thathuman CTGF gene has revealed a negative regulatory
element that was highly homologous to known negative CTGF gene expression is modulated by cell cAMP levels
[51]. Raised cAMP levels or cAMP analogues inhibitregulatory cis elements [49]. These elements are likely
to be involved in differential regulation of CTGF expres- TGF-b’s induction of CTGF in normal rat kidney (NRK)
fibroblasts and NIH 3T3 cells, but not TGF-b–inducedsion (Fig. 1).
Connective tissue growth factor is a cysteine-rich changes in cell morphology [51]. Raised cAMP levels or
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Table 2. Some cell sources and regulation of CTGF CTGF BIOACTIVITIES IN VITRO
Cell type Reference Connective tissue growth factor has diverse bioactivi-
Stimuli ties in vitro (Table 3). Depending on the cell types,
TGF-b Fetal bovine aortic smooth CTGF may trigger mitogenesis, chemotaxis, or matrix
muscle cells [47]
production, prevent proliferation, stimulate apoptosis,Human vascular smooth
muscle cells [60] or modulate angiogenesis. In early reports, CTGF was
Pancreatic cancer cell lines: noted to have mitogenic and chemotactic effects with
Panc-1 and HPAF [45]
NRK fibroblasts and NIH 3T3 cells, respectively, similarHuman chondrosarcoma-
derived chondrocytes [42] to PDGF [8]. CTGF’s mitogenic activity on NRK fibro-
Human lung fibroblasts [81] blasts is augmented by heparin and EGF, and not by
TGF-b1 Human foreskin fibroblasts [35]
TGF-b [36]. The 10 kD form of porcine CTGF is alsoMouse NIH 3T3 cells [35]
Skin fibroblasts from mitogenic for BALB/c 3T3 cells, vascular smooth muscle
patients with scleroderma [40] cells, and endometrial stromal cells, but not endothelial
Human lung fibroblasts [23]
cells [24]. This mitogenic activity is potentiated by IGF,Mouse lung fibroblasts from
BALB/c mice [23] PDGF, EGF, and basic FGF (bFGF). In NIH 3T3 cells
Human gingival fibroblasts [33] and HUVECs, mCTGF (fisp-12) is not mitogenic byTransfected newt blastema
itself, but enhances bFGF-induced DNA synthesis inB1H1 cells [65]
Human breast cancer cell these cells [37]. CTGF is likewise mitogenic for cultured
line MCF-7 [54] fibroblasts from patients with scleroderma [40]. CTGFPrimary human mesangial
also promotes proliferation and differentiation of chon-cells [76]
TGF-b2 Human Hs578T breast drocytes in culture [44].
cancer cells [27] Connective tissue growth factor enhances mRNA lev-Rat mesangial cells [34]
els for a1-type 1 collagen, fibronectin, and a5 integrinTGF-a Pancreatic cancer cell lines:
Panc-1, Patu8988t, and in NRK fibroblasts [36], suggesting a role in matrix pro-
HPAF [45]
duction. Overexpression of CTGF, by transfection ofEGF Pancreatic cancer cell lines:
Panc-1, Patu8988t, and CTGF mRNA into human aortic smooth muscle cells
HPAF [45] (HASCs), inhibits PDGF-stimulated cell proliferation
High glucose Human mesangial cells [76]
and increases apoptosis [53]. The same authors reportedRat mesangial cells [34]
Cyclical mechanical a similar apoptotic effect with a human breast cancer
strain Rat mesangial cells [34] cell line [54].
BMP 2 Human chondrosarcoma
Recently, mCTGF (fisp-12) and cyr 61 have been re-derived chondrocytes [42]
Dexamethasone Mouse BALB/c 3T3 ported to regulate angiogenesis [55]. Specifically, puri-
fibroblasts [38] fied mCTGF protein stimulates adhesion and migra-Inhibitors
tion and promotes survival (by inhibiting apoptosis) ofcAMP analogues NRK fibroblasts, NIH 3T3
cells [51, 52] primary human dermal microvascular endothelial cells
TNF-a Bovine aortic endothelial (HMVECs) [56]. Recombinant CTGF also induces pro-cells [39]
liferation, adhesion, migration, and remodeling of bovineBALB/c 3T3 fibroblasts [38]
aortic endothelial (BAE) cells [41, 57].
With the exceptions of mitogenesis, stimulation of ma-
trix production and apoptosis, the various bioactivities
cAMP analogues also inhibited TGF-b’s induction of of CTGF described earlier in this article, are not all
anchorage-independent growth (AIG) of NRK fibro- shared by TGF-b. Other effects of TGF-b not shared
blasts [51] and TGF-b–induced collagen synthesis in by CTGF include AIG of fibroblasts and inhibition of
NRK fibroblasts and hFFs [52]. The inhibition of AIG epithelial cell growth [36].
but not of collagen synthesis was reversed by the addition The finding that TGF-b can induce CTGF synthesis
of CTGF [51, 52]. Subsequently, cAMP and its analogues and that TGF-b and CTGF share many functions is com-
were observed to reduce CTGF message and protein in patible with the hypothesis that CTGF is a downstream
hFFs [52]. In contrast to this observation, cAMP in- mediator of many of TGF-b’s bioactivities in many sys-
creased CTGF protein (without an increase in mRNA tems. As discussed later in this article, this hypothesis
level) by inhibiting its breakdown in bovine large vessel is further supported by studies employing anti-CTGF
endothelial cells [30]. In the same article, in bovine mi- antibodies to inhibit TGF-b–induced effects. CTGF is
crovessel endothelial cells, cAMP stimulated CTGF deg- essential for TGF-b’s induction of collagen synthesis [52]
radation, suggesting differential regulation of CTGF in and AIG in fibroblasts [58], although CTGF does not in-
duce AIG on its own. This suggested that TGF-b–stimu-microvessel versus large vessel endothelial cells.
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Table 3. Some actions of CTGF in vivo and in vitro
In vitro actions of CTGF
Cell type Bioactivity Reference
NRK fibroblasts Mitogenic [8]
NIH 3T3 cells Chemotactic [8]
NRK fibroblasts Mitogenic effect enhanced by EGF, heparin and TGF-b [36]
NRK fibroblasts No action on AIG growth [36]
NRK fibroblasts Requirement for TGF-b induced AIG growth [58]
NRK fibroblasts Enhances a1 type 1 collagen, fibronectin and a5 integrin formation [36]
NRK fibroblasts and human foreskin fibroblasts TGF-b mediated collagen synthesis and dose-dependent increases
of collagen [52]
NRK fibroblasts Modulation of cell-cycle progression in cAMP-arrested cells [51, 59]
Bovine endothelial cells Stimulates proliferation, migration and tube formation [41, 57]
BALB/c 3T3 cells and bovine smooth muscle cells Mitogenesis (10 kDa fragment of pCTGF) [24]
Human microvascular endothelial cells Promotes cell and migration via av b3 integrin [56]
HUVECs, NIH 3T3 & Mv1Lu cells Promotes cell attachment [37]
HUVECs Enhances mitogenic effect of bFGF [37]
Chondrocytic cell lines, rabbit growth cartilage cells Proliferation and differentiation [44]
Human aortic smooth muscle cells (HASC) Inhibition of cell proliferation stimulated by PDGF and enhanced
apoptosis of cells [53]
Human breast cancer cell line Apoptosis [54]
Rabbit growth cartilages Increased aggrecan and collagen types II and X [44]
Primary human mesangial cells Increased types I and IV collagen and fibronectin levels [76]
Rat mesangial cells Increased type 1 collagen and fibronectin [34]
In vivo actions of CTGF
Tissue Bioactivity Reference
Skin of NIH Swiss mice Nodule formation, increased connective tissue and ECM material [36]
Subcutaneous tissue of BALB/c mice CTGF on its own, causing some edema and cell infiltration, simulta-
neously with and serially after TGF-b, causing fibrotic tissue for-
mation, and serially before TGF-b, causing granulation tissue only [72]
Subcutaneous tissue of Wistar rats Angiogenesis [57]
Corneal micropockets of Sprague-Dawley rats Neovascularization [56]
lated AIG of fibroblasts requires activation of both CTGF- limb blastemas of newts [65], and in various cells of the
rat central nervous system [66].dependent and CTGF-independent pathways [58]. Kinetic
A recent study has demonstrated that CTGF is ex-studies of the induction of DNA synthesis revealed that
pressed in uterine luminal flushings (ULFs) of pigs [24].the CTGF-dependent restriction point of the NRK fi-
There were 10, 16, and 20 kD forms of CTGF (the 38 kDbroblast cell cycle was late in G1 and that CTGF con-
CTGF was not detected in the ULF) that were isolatedtrolled cell cycle progression through late G1- and S-phase
by specific heparin binding. These forms were highlyentry of these cells [51]. Subsequent to this, CTGF was
truncated and showed that the N-terminal two thirds ofreported to trigger S phase entry by reducing p27 (Kip 1)
the primary translational product (domains I to III, thatlevels and thereby increasing cyclin A levels. These
is, IGF, VWF, and TSP modules) was not required forchanges, in turn, resulted in hyperphosphorylation of
mitogenic activity or heparin binding. Ball et al presentedpRb and release of E2F, suggesting that CTGF mediates
evidence that the 16, 18, and 20 kD forms of CTGF areTGF-b–induced fibroblast proliferation by modulating
intermediate mass forms of CTGF and are producedcyclin-dependent kinase (cdk) activities.
with 10 kD CTGF by proteolysis of 38 kD CTGF, which
is a normal physiological process in utero [67]. CTGF
CTGF EXPRESSION AND ACTIONS IN VIVO protein levels were also found in pregnant and normal
Connective tissue growth factor has been detected in uteri of the pigs, suggesting several roles in regulating
many human tissues, including heart, brain, placenta, lung, cell function in the uterine tract. Another study sup-
liver, muscle, kidney, and pancreas [60], and in a variety of ported these roles of CTGF in uterine cell growth, migra-
human biological fluids, for example, serum, pregnancy tion, adhesion, and ECM production during the oestrous
serum, amniotic, follicular, peritoneal, and cerebrospinal cycle and early pregnancy in mice, as well as in the early
fluids [27, 61]. CTGF has also been detected in human development of the embryo [31]. The presence of these
pancreatic islet and ductal cells [45, 62] and in portal CTGF products in various body fluids suggests that they
tracts of human livers [63]. In animals, CTGF has been may be reservoirs of CTGF in vivo [68].
Since its discovery in 1991, the expression of CTGFisolated in various tissues of mice embryos [37, 64], in
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Table 4. Patterns of increased expression of CTGF in disease in vivo levels within seven days. A similar pattern was observed
for induction of TGF-b [71].Tissue Reference
Intradermal injections of CTGF into NIH Swiss miceFibroblasts from patients with systemic sclerosis and
localized scleroderma [69, 70] [36] induced granulation tissue formation and fibrosis
Fibroblasts from human keloid, scar tissue, eosinophilic similar to that observed at the injection site of TGF-b.
fasciitis and Dupuytren’s contracture [70]
In another recent study of a mouse skin fibrosis modelSkin fibroblasts from NIH 3T3 mice treated with TGF-b [36]
Skin fibroblasts from BALB/c mice treated with CTGF [72], induction of persistent fibrosis was demonstrated
or TGF-b3 [72] to require interaction of several growth factors: TGF-b,Skin fibroblasts of BALB/c mice treated with TGF-b2 [82]
for example, being an induction factor, and CTGF, beingFibroblasts and endothelial cells from dermatofibromas
and endothelial cells from pyogenic granulomas [83] a maintenance factor. CTGF mRNA levels remained
Fibroblasts of patients within desmoplastic malignant elevated in those areas of persistent fibrosis, as deter-melanoma [73]
mined by in situ hybridization.Fibrous stroma of human mammary infiltrating tumors
and fibroblasts of murine mammary tumor models [84] Intradermal cAMP analogue injections into transgenic
Pancreatic fibroblasts of patients with chronic pancreatitis [62] mice with a human CTGF promoter/lacZ reporter trans-Fibrotic areas in patients with pancreatic cancers [45]
Fibrotic areas of chronic human hepatitis [63] gene [52] suppressed TGF-b’s activation of this transgene.
Centrilobular and fibrous septa of models of liver fibrosis These analogues were then used to block TGF-b–induced
in rats [63]
collagen deposition in Schilling-Hunt chambers insertedSera of patients with biliary atresia [61]
Inflammatory areas of patients with Crohn’s disease and into wounds of Sprague-Dawley rats and to reduce der-
ulcerative colitis, and fibrotic stenotic areas of patients mal fibroblast populations induced by injecting TGF-b
with Crohn’s disease [85]
into the dermis of NIH Swiss mice [52]. Collectively,Lung fibrosis model of bleomycin-sensitive mice [23]
Transbronchial biopsies of patients with idiopathic these observations indicate that CTGF mediates TGF-b–
pulmonary fibrosis [86] induced fibroblast collagen synthesis, and that in vivoBronchoalveolar lavage fluid of patients with idiopathic
blockade of CTGF synthesis or action reduces TGF-b–pulmonary fibrosis and pulmonary sarcoidosis [28]
Cardiac myocytes and mesenchymal cells in infarct zone induced granulation tissue formation by inhibiting colla-
of rat myocardium [87]
gen synthesis and fibroblast accumulation.Lens epithelial cells of patients with anterior polar and
nuclear cataracts [88] In two other in vivo models, CTGF was confirmed
Fibrotic areas of atherosclerotic plaques [60] to play a role in angiogenesis where CTGF placed on
Heart, kidney & skin of BALB/c mice injected with
chorioallantoic membranes of chick embryos formeddexamethasone [38]
small vessels and injection of CTGF into the backs of
Wistar rats promoted vessel formation [57].
has also been explored in various human diseases and CTGF SIGNAL TRANSDUCTION
animal models of disease. CTGF mRNA has been de-
The mechanisms by which CTGF exerts its effects ontected in fibroblasts of sclerotic lesions of patients with
cells are still being appreciated. In initial reports, CTGFsystemic sclerosis by in situ hybridization [69]. In patients
bound to the surface of NIH 3T3 cells with relativelywith localized scleroderma, more CTGF mRNA was de-
high affinity, and this binding could be competed withtected in fibroblasts in tissue from the sclerotic stage than
increasing concentrations of recombinant PDGF BB [8].the inflammatory stage, indicating a close correlation
CTGF has also been reported to interact with a PDGFbetween CTGF and fibrosis. This was also true for keloid
a receptor in scleroderma fibroblasts [40]. This suggestedtissue and fibrotic areas of eosinophilic fasciitis, nodular
that the CTGF peptide binds to a certain class of PDGFfasciitis, and Dupuytren’s contractures [70]. Subsequently,
receptor (PDGF-R) or there is some cross reactivity ofexpression of CTGF has been reported in a variety of
PDGF BB with CTGF receptors. mCTGF, as describeddiseases (Table 4).
earlier, is present in the media of NIH 3T3 cells and wasIn a model of wound healing in which stainless steel
shown to be internalized and degraded through lyso-mesh chambers were implanted into the flanks of Fisher
somal pathways, implying cell surface receptor interac-rats [35], TGF-b expression preceded CTGF expression
tions [37].by about six days, suggesting that, in vivo CTGF may
The soluble 10 kD form of CTGF does not bind to thebe a downstream mediator of TGF-b. This effect of
PDGF-R, however, but stimulates mitosis in fibroblastsTGF-b was again proposed to be with mesenchymal-
[29]. This observation points to the existence of multiplederived cells, that is, endothelial cells and fibroblasts. In
and possibly CTGF-specific cell surface receptors.another model of wound healing in which the skin and
A human chondrocyte cell line expresses another pu-panniculus carnosus of the back of BALB/c mice was
tative CTGF receptor [32] that is larger (240 kD) thanexcised [38], CTGF mRNA was maximally expressed at
12 to 24 hours after wounding and returned to basal the PDGF type b receptor previously reported by Brad-
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Table 5. CTGF expression by renal cells in vitro
Cell type Species Stimulus Reference
Glomerular endothelial cells Not reported Not reported Not reported
Glomerular mesangial cells Human 30 mmol/L glucose [76]
Human TGF-b1 [76]
Rat 20 mmol/L and 35 mmol/L glucose [34]
Rat TGF-b2 [34]
Rat Cyclical mechanical strain [34]
Rat CTGF [34]
Renal epithelial BSC cells African green monkey Scrape wounding [79]
African green monkey Calcium oxalate crystals [80]
Table 6. CTGF expression in renal disease in vivo
Disease Species Distribution Reference
Streptozotocin-induced diabetes Rats Cortex and glomeruli [76]
DbDb diabetes Mice Glomeruli [34]
IgAN Human Crescents, glomeruli, and tubulointerstitium [75]
CGN Human Crescents, glomeruli, and tubulointerstitium [75]
DN Human Glomeruli [75]
Diffuse LN Human Crescents, glomeruli, and tubulointerstitium [75]
MPGN Human Glomeruli and tubulointerstitium [75]
FGS Human Glomeruli, extracapillary lesions and tubulointerstitium [75]
CTR Human Glomeruli and tubulointerstitium [75]
MN with fibrosis Human Glomeruli, extracapillary lesions and tubulointerstitium [75]
Abbreviations are: IgAN, immunoglobulin A nephropathy; CGN, crescentic glomerulonephritis; DN, diabetic nephropathy; diffuse LN, diffuse lupus nephritis;
MPGN, mesangioproliferative glomerulonephritis; FGS, focal glomerulosclerosis; CTR, chronic transplant rejection; MN, membranous nephritis.
ham et al [8] and Kubo et al [73], and than the PDGF lated or remained normal in minimal-change nephrotic
type a receptor described by Kikuchi et al [40]. syndrome (MCNS), idiopathic membranous nephropa-
mCTGF and cyr 61 appear to modulate angiogenesis via thy (MN), and acute post-infectious glomerulonephritis.
integrin receptors. Specifically, the effects of mCTGF on en- In glomerular lesions, CTGF expression was increased
dothelial cell adhesion, migration, survival, and angiogene- in cellular crescents of CGN, IgAN, and diffuse LN (pro-
sis appear to involve an a5b3 (integrin receptor)-dependent liferating epithelial cells and not macrophages or fibro-
pathway [56]. This integrin connection is further sup- blasts were the main components of these crescents), as
ported by another study whereby activation-dependent well as in the fibrocellular crescents. In addition, CTGF
adhesion of platelets to mCTGF is mediated through was increased in other extracapillary lesions, such as areas
integrin aIIbb3 [74]. of segmental sclerosis with adhesion to Bowman’s capsule
in FGS and MN with fibrosis. CTGF was highly expressed
in glomeruli of patients with IgAN, diabetic nephropathyPUTATIVE ROLE IN GLOMERULOSCLEROSIS
(DN), and diffuse LN where there was mesangial prolif-AND TUBULOINTERSTITIAL FIBROSIS
eration. With regard to the tubulointerstitium, CTGFWhereas CTGF has been described in various human
mRNA was markedly increased in patients with CTRtissues, it is most abundant in the kidney [60]. In normal
and chronic tubulointerstitial damage associated withrenal tissue, CTGF mRNA has been demonstrated by in
glomerulonephritis, and this expression was localized tositu hybridization in visceral and parietal epithelial cells,
a-smooth muscle actin-positive cells (myofibroblasts), asin some interstitial cells of the periglomerular and peritu-
well as in areas of periglomerular fibrosis. CTGF-positivebular areas, in endothelial cells of peritubular capillaries,
cells, however, were rarely seen in the tubulointerstitiumand probably in interstitial fibroblasts [75]. Increased
of patients with MCNS, FGS, and MN without fibrosis.CTGF mRNA expression has been reported in a variety
In vessels, CTGF expression was increased in smoothof inflammatory glomerular and tubulointerstitial lesions
muscle and endothelial cells.[75] in association with cellular proliferation and matrix
Recent in vivo studies have highlighted increased ex-deposition, including IgA nephropathy (IgAN), chronic
pression of CTGF mRNA in glomeruli of rats with strep-transplant rejection (CTR), crescentic glomerulonephri-
tozotocin-induced DN [76] and the db/db diabetic micetis (CGN), focal glomerulosclerosis (FGS), class IV lupus
[34], implicating CTGF in the development of diabeticnephritis (LN), and membranoproliferative glomerulo-
nephritis (MPGN). CTGF was only minimally up-regu- glomerulosclerosis (Tables 5 and 6).
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Studies with cultured human cells in vitro have shed ference with its profibrotic effects, and may antecede the
development of novel antifibrotic therapies that targetlight on the mechanisms by which CTGF is induced and
on its functional significance in this setting. CTGF mes- the integral CTGF system.
sage is up-regulated in primary human mesangial cells
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